Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
In the EMPEROR-Preserved trial (1):
NICE state (2):
NICE committee stated "..evidence from a clinical trial shows that empagliflozin plus standard care reduces the combined risk of dying from cardiovascular causes or likelihood of first hospitalisation for heart failure compared with placebo plus standard care. There is no clinical trial evidence directly comparing empagliflozin with dapagliflozin. The trials for empagliflozin and dapagliflozin have some differences, including the populations included in the trials and how outcomes are defined. When adjustments for these differences are made, an indirect comparison suggests the treatments have similar clinical effectiveness and a similar effect on quality of life.
A cost comparison suggests empagliflozin has similar costs to dapagliflozin. So, empagliflozin is recommended. Empagliflozin should be started on the advice of a heart failure specialist..."
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.